For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission

Detalhes bibliográficos
Autor(a) principal: Silva,Luiza Soares Vieira da
Data de Publicação: 2017
Outros Autores: Crusoe,Edvan de Queiroz, Souza,Lais Rocha Guimarães de, Chiattone,Carlos Sérgio, Hungria,Vânia Tietsche de Moraes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331
Resumo: Abstract Background: The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients. Methods: A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques. Results: A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29-87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value = 0.0075). Conclusion: The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival.
id ABHHTC-1_df5551b342b5f862e3dc94717a0e303d
oai_identifier_str oai:scielo:S1516-84842017000400331
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remissionAbnormal protein bandOligoclonal bandsMultiple myelomaPrognosisAbstract Background: The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients. Methods: A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques. Results: A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29-87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value = 0.0075). Conclusion: The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2017-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331Revista Brasileira de Hematologia e Hemoterapia v.39 n.4 2017reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1016/j.bjhh.2017.05.010info:eu-repo/semantics/openAccessSilva,Luiza Soares Vieira daCrusoe,Edvan de QueirozSouza,Lais Rocha Guimarães deChiattone,Carlos SérgioHungria,Vânia Tietsche de Moraeseng2017-12-08T00:00:00Zoai:scielo:S1516-84842017000400331Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2017-12-08T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
title For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
spellingShingle For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
Silva,Luiza Soares Vieira da
Abnormal protein band
Oligoclonal bands
Multiple myeloma
Prognosis
title_short For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
title_full For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
title_fullStr For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
title_full_unstemmed For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
title_sort For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
author Silva,Luiza Soares Vieira da
author_facet Silva,Luiza Soares Vieira da
Crusoe,Edvan de Queiroz
Souza,Lais Rocha Guimarães de
Chiattone,Carlos Sérgio
Hungria,Vânia Tietsche de Moraes
author_role author
author2 Crusoe,Edvan de Queiroz
Souza,Lais Rocha Guimarães de
Chiattone,Carlos Sérgio
Hungria,Vânia Tietsche de Moraes
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Silva,Luiza Soares Vieira da
Crusoe,Edvan de Queiroz
Souza,Lais Rocha Guimarães de
Chiattone,Carlos Sérgio
Hungria,Vânia Tietsche de Moraes
dc.subject.por.fl_str_mv Abnormal protein band
Oligoclonal bands
Multiple myeloma
Prognosis
topic Abnormal protein band
Oligoclonal bands
Multiple myeloma
Prognosis
description Abstract Background: The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients. Methods: A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques. Results: A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29-87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value = 0.0075). Conclusion: The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival.
publishDate 2017
dc.date.none.fl_str_mv 2017-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjhh.2017.05.010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.39 n.4 2017
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213112991449088